SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
SEC Accession No. 0001104659-21-010174
Filing Date
2021-02-01
Accepted
2021-02-01 16:09:18
Documents
4
Group Members
NOVARTIS AG

Document Format Files

Seq Description Document Type Size
1 SC 13G tm214797d3_sc13g.htm SC 13G 64177
2 EXHIBIT 99.1 tm214797d3_ex99-1.htm EX-99.1 16929
3 EXHIBIT 99.2 tm214797d3_ex99-2.htm EX-99.2 6015
4 EXHIBIT 99.3 tm214797d3_ex99-3.htm EX-99.3 6904
  Complete submission text file 0001104659-21-010174.txt   95860
Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Filed by) CIK: 0001297709 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 500 ARSENAL STREET SUITE 100 WATERTOWN MA 02472
Business Address 500 ARSENAL STREET SUITE 100 WATERTOWN MA 02472 617-679-1970
Forma Therapeutics Holdings, Inc. (Subject) CIK: 0001538927 (see all company filings)

IRS No.: 371657129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-91541 | Film No.: 21576801
SIC: 2836 Biological Products, (No Diagnostic Substances)